drugset / Trial / NCT01812018
Endostar + GT in Pulmonary Metastases of Soft Tissue Sarcoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this exploratory phase II study is to assess the effectiveness and safety profile of Endostar®(Recombinant Human Endostatin Injection) plus Gemcitabine and Docetaxel in treatment of soft tissue sarcoma patients with pulmonary metastases.
Timeline
- Start
- 2012-11
- Primary completion
- 2015-04
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Endostar | Protein / enzyme biologic | 7.5 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |